Immunotherapy and targeted therapy for kidney cancer spread to liver
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs — envaflolimab (an immunotherapy that helps your immune system fight cancer) and lenvatinib (a targeted therapy that blocks tumor blood vessel growth) — for people with a specific type of kidney cancer that has spread to the liver. The goal is to see if this combo can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have clear cell renal cell carcinoma (a specific type of kidney cancer) that has spread to the liver.
- You should not have received any prior systemic (whole-body) treatment for your cancer, though you may have had radiation therapy or certain neoadjuvant treatments.
- You need to have at least one measurable liver tumor (visible and large enough on a CT scan).
- You must be in generally good health (able to care for yourself, with a life expectancy of at least 3 months) and have adequate organ function (like liver, kidney, and blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, cardenilimab and lenvatinib, given before and after surgery to remove kidney cancer. The goal is to see if this approach helps prevent the cancer from coming back. It is for people with early-stage (non-spread) clear cell kidney cancer who are healthy enough for surgery.
This trial tests a new combination of two drugs (envafolimab and axitinib) as the first treatment for advanced kidney cancer that has spread or cannot be removed. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of immunotherapy and targeted drugs (called IO/TKI) given before and after surgery for clear cell renal cell carcinoma (a type of kidney cancer). The goal is to shrink tumors and improve survival outcomes.
This trial tests a combination of targeted radiation, an oral drug (axitinib), and an immunotherapy (toripalimab) for people with kidney cancer that has spread to a few spots. It aims to see if this combo helps control the cancer longer.
This trial is testing a new treatment for people with advanced kidney cancer that has spread to other parts of the body. It aims to find a better way to manage the disease.
This trial tests a combination of immunotherapy drugs (fianlimab, cemiplimab, and possibly ipilimumab) compared to another immunotherapy combo (ipilimumab + nivolumab) for people with advanced kidney cancer who have not had previous treatment. The goal is to see which combination works better.
Hear when a new Clear Cell Renal Cell Cancer (ccRCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.